PURPOSE: We aimed to compare the efficacy of a gonadotropin-releasing hormone (GnRH) antagonist protocol and a GnRH agonist long protocol used in the first in vitro fertilization-embryo transfer (IVF-ET) cycle in an unspecified population of infertile couples. METHODS: Fifty and 34 patients were treated with a GnRH agonist long protocol (agonist group) and GnRH antagonist protocol (antagonist group), respectively, in the first treatment cycle. The primary and secondary outcome measures were cumulative live birth rates after fresh and cryopreserved-thawed ETs and incidence of grades II and III ovarian hyperstimulation syndrome (OHSS), respectively. RESULTS: No significant differences were observed in clinical pregnancy rates (38.0 vs. 32.4%) and live birth rates (22.0 vs. 23.5%), which included both fresh and cryopreserved-thawed ETs, between the 2 groups. However, the incidence of grade III OHSS was significantly lower with the GnRH antagonist protocol than the GnRH agonist long protocol. CONCLUSIONS: Used in the first IVF-ET cycle in an unspecified population of infertile patients, the GnRH antagonist protocol showed the same clinical outcome as the GnRH agonist long protocol.
PURPOSE: We aimed to compare the efficacy of a gonadotropin-releasing hormone (GnRH) antagonist protocol and a GnRH agonist long protocol used in the first in vitro fertilization-embryo transfer (IVF-ET) cycle in an unspecified population of infertile couples. METHODS: Fifty and 34 patients were treated with a GnRH agonist long protocol (agonist group) and GnRH antagonist protocol (antagonist group), respectively, in the first treatment cycle. The primary and secondary outcome measures were cumulative live birth rates after fresh and cryopreserved-thawed ETs and incidence of grades II and III ovarian hyperstimulation syndrome (OHSS), respectively. RESULTS: No significant differences were observed in clinical pregnancy rates (38.0 vs. 32.4%) and live birth rates (22.0 vs. 23.5%), which included both fresh and cryopreserved-thawed ETs, between the 2 groups. However, the incidence of grade III OHSS was significantly lower with the GnRH antagonist protocol than the GnRH agonist long protocol. CONCLUSIONS: Used in the first IVF-ET cycle in an unspecified population of infertile patients, the GnRH antagonist protocol showed the same clinical outcome as the GnRH agonist long protocol.
Authors: F Olivennes; J Belaisch-Allart; J C Emperaire; H Dechaud; S Alvarez; L Moreau; B Nicollet; J R Zorn; P Bouchard; R Frydman Journal: Fertil Steril Date: 2000-02 Impact factor: 7.329
Authors: Trifon G Lainas; Ioannis A Sfontouris; Ioannis Z Zorzovilis; George K Petsas; George T Lainas; Efthymia Alexopoulou; Efstratios M Kolibianakis Journal: Hum Reprod Date: 2009-12-15 Impact factor: 6.918
Authors: Paul Devroey; Mohamed Aboulghar; Juan Garcia-Velasco; Georg Griesinger; Peter Humaidan; Efstratios Kolibianakis; William Ledger; Candido Tomás; Bart C J M Fauser Journal: Hum Reprod Date: 2009-01-19 Impact factor: 6.918
Authors: George Griesinger; Christos A Venetis; Tanja Marx; Klaus Diedrich; Basil C Tarlatzis; Efstratios M Kolibianakis Journal: Fertil Steril Date: 2007-12-03 Impact factor: 7.329